These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 18157598)
41. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073 [TBL] [Abstract][Full Text] [Related]
42. Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer. Lim JU; Woo IS; Jung YH; Byeon JH; Park CK; Kim TJ; Kim HR Korean J Intern Med; 2014 Nov; 29(6):830-3. PubMed ID: 25378985 [No Abstract] [Full Text] [Related]
43. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. Hata A; Kaji R; Fujita S; Katakami N J Thorac Oncol; 2011 Mar; 6(3):653-4. PubMed ID: 21317753 [No Abstract] [Full Text] [Related]
44. Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. Gandara DR; Wakelee H; Calhoun R; Jablons D J Thorac Oncol; 2007 Jul; 2(7 Suppl 3):S125-7. PubMed ID: 17603308 [TBL] [Abstract][Full Text] [Related]
45. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Smith J Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289 [TBL] [Abstract][Full Text] [Related]
47. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA; J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829 [TBL] [Abstract][Full Text] [Related]
48. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Gridelli C; Maione P; Bareschino MA; Schettino C; Sacco PC; Ambrosio R; Barbato V; Falanga M; Rossi A Anticancer Res; 2010 Apr; 30(4):1301-10. PubMed ID: 20530444 [TBL] [Abstract][Full Text] [Related]
49. [Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies]. Thonnard AS; Bosquée L; Corhay JL Rev Med Liege; 2011 Mar; 66(3):121-5. PubMed ID: 21560426 [TBL] [Abstract][Full Text] [Related]
50. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Scagliotti GV; Novello S; Schiller JH; Hirsh V; Sequist LV; Soria JC; von Pawel J; Schwartz B; Von Roemeling R; Sandler AB Clin Lung Cancer; 2012 Sep; 13(5):391-5. PubMed ID: 22440336 [TBL] [Abstract][Full Text] [Related]
51. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500 [TBL] [Abstract][Full Text] [Related]
53. Erlotinib in the treatment of advanced squamous cell NSCLC. Fiala O; Pesek M; Finek J; Krejci J; Havel L; Hrnciarik M; Salajka F; Bortlicek Z; Benesova L; Minarik M Neoplasma; 2013; 60(6):676-82. PubMed ID: 23906302 [TBL] [Abstract][Full Text] [Related]
54. Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer. Wang Q; Wang H; Li P; Zhu H; He C; Wei B; Ma J; Ma Z Am J Med Sci; 2010 Oct; 340(4):321-5. PubMed ID: 20601859 [TBL] [Abstract][Full Text] [Related]
55. Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer. Popat S; Barbachano Y; Ashley S; Norton A; O'Brien M Lung Cancer; 2008 Feb; 59(2):227-31. PubMed ID: 17920156 [TBL] [Abstract][Full Text] [Related]
56. Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer. Stewart DJ J Natl Cancer Inst; 2008 Mar; 100(6):445-6; author reply 446. PubMed ID: 18334712 [No Abstract] [Full Text] [Related]